Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer

Cancer Research - United States
doi 10.1158/0008-5472.can-16-1055
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway

Clinical Cancer Research
Cancer ResearchOncology
2011English

Flightless I Homolog Represses Prostate Cancer Progression Through Targeting Androgen Receptor Signaling

Clinical Cancer Research
Cancer ResearchOncology
2015English

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer

Cancer Research
Cancer ResearchOncology
2010English

Aberrant Activation of Androgen Receptor in a New Neuropeptide-Autocrine Model of Androgen-Insensitive Prostate Cancer

Cancer Research
Cancer ResearchOncology
2009English

Mechanisms of Acquired Resistance to Androgen Receptor Targeting Drugs in Castration-Resistant Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2014English

Collateral Resistance to Taxanes in Enzalutamide-Resistant Prostate Cancer Through Aberrant Androgen Receptor and Its Variants

Cancer Science
Cancer ResearchMedicineOncology
2018English

Heat Shock Protein 70 Inhibitors Suppress Androgen Receptor Expression in LNCaP95 Prostate Cancer Cells

Cancer Science
Cancer ResearchMedicineOncology
2017English

Prostate Cancer Characteristics Associated With Response to Pre-Receptor Targeting of the Androgen Axis

PLoS ONE
Multidisciplinary
2014English

Looking Beyond Androgen Receptor Signaling in the Treatment of Advanced Prostate Cancer

Advances in Andrology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy